Ask AI
ProCE Banner Activity

Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma

Podcast Episodes

Enhance your knowledge and optimize treatment for patients with R/R MM by learning from subject matter experts Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, in this podcast. Listen as they discuss various strategies to optimize the use of bispecific antibodies in their practices through patient monitoring, dosing in outpatient settings, and utilizing tocilizumab and IVIG among other management strategies. 

Released: May 07, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC. in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for hematologists/oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists and other healthcare professionals involved in the care and treatment of patients with RRMM.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret pivotal clinical trial data on BCMA bispecific antibodies, including efficacy, safety, and use in earlier lines of therapy

  • Apply evidence-based strategies to initiate BCMA BsAb therapy and monitor for key adverse events (eg, CRS, ICANS, infections) across diverse practice settings

  • Design multidisciplinary care coordination strategies to support therapy adherence and treatment continuation in patients transitioning from academic to community settings

  • Integrate patient education and shared decision-making tools to align treatment with patient goals and improve persistence

Disclosure

Primary Author

Muhamed Baljevic, MD, FACP: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb/Celgene, Janssen Biotech, Johnson & Johnson, Pfizer, Prothena, Sanofi/Genzyme, Xilis; researcher: Pfizer; other financial or material support: Parexel International.

Jonathan Ticku, MD, has no relevant financial relationships to disclose.